Agp Limited · PSX:AGP
Agp — Q1 2026 Earnings Presentation
25 slides from Agp's earnings presentation, May 29, 2026
Slide 1: Corporate Briefing Session
Corporate Briefing Session June 1, 2026
Slide 2: AGP Management Representatives
AGP MANAGEMENT REPRESENTATIVES Muhammad Kamran Nasir Group Chief Executive Officer Muhammad Kamran Mirza Executive Director – OBS Group Junaid Aslam Chief Financial Officer Muhammad Asad Khan Company Secretary 2
Slide 3: Table of Contents
TABLE OF CONTENTS Corporate Profile Financial Performance Merger Overview OBS Pharma Overview Questions and Answers 3
Slide 4: Corporate Profile
CORPORATE PROFILE 4
Slide 5: Board of Directors
CORPORATE PROFILE BOARD OF DIRECTORS Tariq Moinuddin Khan Muhammad Kamran Nasir Zafar Iqbal Sobani Maleeha Bangash Chairman Chief Executive Officer Independent Director Independent Director Kamran Nishat Mahmud Yar Hiraj Muhammad Kamran Mirza Non-Executive Director Non-Executive Director Non-Executi
Slide 6: Our Journey
CORPORATE PROFILE OUR JOURNEY 1989 1991 1995 2003 2007 2013 2014 Signs an agreement Acquired 30% OBS-led AGP (Pvt.) Ltd. Enters into a JV Purchase Eli Lilly Purchase UCB consortium with UCB Belgium stake of Eli Lilly starts with Eli Lilly to manufacture & brand rights for brand rights for (through a
Slide 7: AGP Limited Company Profile
COMPANY PROFILE AGP LIMITED WHO WE ARE AGP Limited is one of Pakistan's premier pharmaceutical companies, originating from the former Eli Lilly joint venture. Incorporated in 1989 and listed on the Pakistan Stock Exchange, AGP has evolved into a diversified healthcare group spanning branded pharmace
Slide 8: Leading Brands of AGP & Subsidiaries
CORPORATE PROFILE LEADING BRANDS OF AGP & SUBSIDIARIES Recently launched PKR 4.8 bn PKR 4.3 bn PKR 2.4 bn PKR 2.0 bn PKR 1.8 bn Products in AGP USD 17.1mn USD 15.1mn USD 8.5mn USD 7.0mn USD 6.3mn PKR 0.9 bn PKR 0.8 bn PKR 0.8+ bn PKR 0.7+ bn PKR 0.5 bn USD 3.3mn USD 3.0mn USD 3.0mn USD 2.6mn USD 1.6
Slide 9: Financial Performance
FINANCIAL PERFORMANCE 9
Slide 10: Financial Performance - Q1 2026 AGP Ltd Consolidated
FINANCIAL PERFORMANCE - Q1 2026 AGP LTD- CONSOLIDATED Net Sales (PKR Mn) PAT & PAT Attributable (PKR Mn) 8000 140% 1200 7,160 1,057 123% 6,850 7000 120% 968 1000 5,920 6000 100% 800 853 857 5000 80% 613 3,899 4000 3,661 60% 600 52% 467 556 3000 40% 384 396 400 2000 1,756 1,642 21% 20% 384 400 356 7%
Slide 11: Strong Revenue Growth Despite Economic Challenges
FINANCIAL PERFORMANCE STRONG REVENUE GROWTH DESPITE ECONOMIC CHALLENGES 28,890 3,816 25,034 8,213 3,237 18,743 6,257 1,673 14,459 5,057 4,571 9,317 16,861 1,896 15,540 6,850 12,013 972 9,887 1,594 6,946 7,420 4,284 2020 2021 2022 2023 2024 2025 Q1 2026 AGP (PKR mn) OBS AGP (PKR mn) OBS PK (PKR mn) R
Slide 12: Financial Snapshot – AGP Consolidated
FINANCIAL PERFORMANCE FINANCIAL SNAPSHOT – AGP CONSOLIDATED (Figures in PKR mn) Dec-21 Dec-22 Dec-23 Dec-24 Dec-25 Mar- 26 Sales 9,317 14,459 18,743 25,034 28,890 6,850 Cost of sales (4,262) (7,128) (8,703) (10,482) (11,635) (2,857) Gross profit 5,055 7,331 10,040 14,551 17,255 3,993 Administrative
Slide 13: Merger Overview
MERGER OVERVIEW 13
Slide 14: Current Group Structure
MERGER OVERVIEW CURRENT GROUP STRUCTURE Aitkenstuart Pakistan (Pvt.) Ltd. (Local Holdco) 100% 55.8% 80% Aspin Pharma (Pvt.) Ltd. 4.79% AGP Ltd. OBS Pharma (Pvt.) Ltd. (Former J&J Business) (Former Eli Lilly Business) (Former Bayer Business) 65% 91.82% 28% 2.73% OBS AGP (Pvt.) Ltd. OBS Pakistan (Pvt.
Slide 15: Post-Merger Group Structure
MERGER OVERVIEW POST-MERGER MERGER GROUP STRUCTURE Aitkenstuart Aitken Business Assets AGP 100% AGP AGP Business Assets Other Shareholders Aspin OBS AGP OBS AGP Business Assets Other Shareholders OBS Pakistan OBS Pakistan Business Assets Other Shareholders OBS Pharma OBS Pharma Business Assets Other
Slide 16: Proforma Financials as of 31-Dec-25
MERGER OVERVIEW PROFORMA FINANCIALS AS OF 31-DEC-25 Revenue (PKR bn) EBITDA (PKR bn) Profit Attributable to Shareholders of AGP (PKR bn) 37.5 5.6 28.9 11.8 8.6 3.7 Existing Post-Scheme Existing Post-Scheme Existing Post-Scheme EPS (PKR / Share) Long-Term Debt (PKR bn) 14.7 15.9 13.3 8.2 3.1 3.9 Exis
Slide 17: Strategic Synergies
MERGER OVERVIEW STRATEGIC SYNERGIES Manufacturing, Distribution & Supply Portfolio Diversification & Reduced Synergies & Financial Optimization Chain Synergies Business Risk Consolidate operations across manufacturing, 1 distribution, and supply chain for improved 4 Diversify across therapeutic segm
Slide 18: Long Term Debt Trend
MERGER OVERVIEW LONG TERM DEBT TREND Merged Entity Long-Term Debt Balance (PKR bn) 15.9 11.9 8.3 5.0 2.0 - Dec-25 Dec-26 Dec-27 Dec-28 Dec-29 Dec-30 LT Debt / EBITDA 1.3 0.7 0.4 0.2 0.1 18
Slide 19: OBS Pharma Overview
OBS PHARMA OVERVIEW 19
Slide 20: OBS Pharma Corporate Profile
OBS PHARMA OVERVIEW CORPORATE PROFILE ~PKR 8.7* Bn ~52% CY25 Revenue CY25 Gross Margin ~PKR 1.4 Bn 3 Acres CY25 Profit After Tax Manufacturing Facility COMPANY OVERVIEW THERAPEUTIC SEGMENTS OBS Pharma (Pvt.) Limited is one of Pakistan's leading Pre-term birth prevention, Gynae infections, Menstrual
Slide 21: Income Statement March 2026
OBS PHARMA OVERVIEW INCOME STATEMENT MARCH 2026
Slide 22: Product Portfolio - Women Health Care
OBS PHARMA OVERVIEW PRODUCT PORTFOLIO - WOMEN HEALTH CARE PKR 3.2 Bn PKR 2.0 Bn PKR 1.3 Bn Pre-Term Birth Menstrual Cycle Gynecological Calcium Supplement Iron Deficiency Prevention Regulation infections Menopausal Fertility Treatment Fertility Treatment Pregnancy Support Mineral Supplement Symptoms
Slide 23: Product Portfolio - Specialty Healthcare
OBS PHARMA OVERVIEW PRODUCT PORTFOLIO - SPECIALTY HEALTHCARE PKR 134 Mn PKR 224 Mn PKR 85 Mn Male Sex Hormone Male Sex Hormone Insomnia Men's Health Supplement Bacterial Infections Urinary Retention Renal Function Anti-Malarial Source: Latest IQVIA MAT MAR 2026
Slide 24: Product Portfolio - Consumer Healthcare
OBS PHARMA OVERVIEW PRODUCT PORTFOLIO - CONSUMER HEALTHCARE PKR 1.0 Bn PKR 530 Mn PKR 174 Mn Irritated Skin Acne Treatment Various Skin Conditions Anti Inflammatory Foot and Vaginal Infections Hair Health Acne and Skin Discoloration Body Lotion Source: Latest IQVIA MAT MAR 2026
Slide 25: Questions & Answers
QUESTIONS & ANSWERS 25